https://www.selleckchem.com/products/ltx-315.html
Bedaquiline (BDQ) is recommended for the treatment of multidrug-resistant tuberculosis (MDR T, however, it has the potential to prolong QTc interval. We assessed the frequency and severity of QTc prolongation in patients receiving BDQ in California. Based on chart review for patients receiving BDQ as part of MDR TB therapy from January 2013-May 2019, we analyzed QTc values at six pre-specified time points during BDQ therapy (baseline, 2, 4, 8, 12, and 24weeks), as well as peak QTc, time to peak QTc, and the clinical characteristics of
Like
Comment
Share
